Detailed Narrative
2026 growth-first strategy and investment stance
Management framed 2026 as a year to 'seize industry opportunities and make growth our top priority,' explicitly accepting flat operating profit in exchange for scale. The playbook is the one validated in 2025: public-domain user targeting funded by aggressive traffic spend, now paired with AI tooling to lift conversion and service efficiency. The CEO positioned the resulting user-base expansion as the foundation for long-term development, with profit harvest deferred to future years. The call as transcribed contained no analyst Q&A despite the IR host indicating questions would be taken, so all content is management-scripted.
Insurance business: user acquisition, channel ROI optimization and product iteration
The quarter's 74.1% insurance income growth reflects continued step-up in public-domain user targeting and traffic-plus-AI investment. Sequentially, income declined because management proactively cut lower-ROI channels — a curation move that lifted segment operating margin 2 points QoQ — while expanding into other high-quality traffic channels and running mature ones with refined operations to keep improving ROI. On the product side the company kept iterating for underserved users: pre-existing-condition and disability products grew, the inclusive cancer medical product was upgraded, and a new cancer-specific product lowered the bar to lifelong cancer protection. Aftersales service was upgraded with a dedicated customer-complaint hotline, payment channels connected into the customer-service system for faster response processing, and simplified procedures plus a fast-track channel for elderly customers served via their children.
AI-native transformation across the platform
Waterdrop says it is accelerating its shift toward an 'AI native company.' As of March 31, 2026 it had filed 75 LLM-related patent applications (9 international) and was recently granted 2 more national invention patents in intelligent semantic understanding and multimodal recognition, with the technology to be progressively applied to insurance scenarios such as intelligent customer service and claims. In insurance operations, user-facing AI tools (AI insurance expert, AI medical insurance expert, WeCom AI) work across the mini program, WeChat, phone and WeCom; a consultant-facing 'Claude Copilot' (as transcribed — the product name may be ASR-garbled) entered internal beta on CRM and WeCom in late March, combining the product knowledge base and agent tools for instant underwriting answers, sales review, top-track play refining and performance analysis. The low-code platform waterdrop.ai now offers 30+ purpose-built agents for internal teams and external clients. In crowdfunding, an AI-assisted review model upgrade structures campaign material for preliminary screening, shortening intake and first-pass review while freeing risk specialists for complex cases.
Medical crowdfunding: scale, AI review and service inclusivity
The crowdfunding platform remains stable, with two stated priorities this quarter: AI capability building and better service in diverse regions. Beyond the AI review upgrade, the company improved service in linguistically diverse communities — adding minority-language specialists to work alongside campaign consultants on upfront consultation, document guidance and dispute resolution, and standing up a dedicated team where translators and risk-control specialists track each case end-to-end, maintaining strict risk-control compliance while respecting local cultural sensitivities.
Digital clinical trial solutions: enrollment growth and matching-engine buildout
The healthcare/digital clinical trial business sustained what management called high-quality growth, partnering with 243 pharmaceutical companies and CROs and initiating services for 128 new programs in the quarter. In January 2026 its intelligent drug-patient matching technology secured a national invention patent — the first of its kind in China. The quarter's focus was upstream data-structuring capability connected to the matching engine, establishing a standardized pipeline from data structuring to intelligent product matching that generates suitability recommendations against trial protocols, while building a medical case library across complex indications and rare cancers with a more balanced therapeutic-area mix for mid-to-long-term growth.
Cost structure, profitability and transcription caveats
Total operating costs and expenses were approximately RMB 1.16 billion, stated as 'up about 1.5% year-over-year' — almost certainly an ASR error given the tripling of marketing spend and only 5.3% operating-profit growth on 64.8% revenue growth. G&A fell 4.3% YoY to RMB 71.7 million on lower professional service fees; R&D rose 11.5% YoY to RMB 62.7 million, driven by an ~RMB 6.7 million increase in cloud and technical services. The CFO's remark that noninsurance businesses 'accounted for about 70.8% of total revenue' is another apparent ASR error — the stated components (service fees ~RMB 60.73 million plus clinical-trial income ~RMB 24.2 million) imply roughly 7% of revenue. Insurance segment operating profit of RMB 150 million exceeds the ~RMB 80 million company operating profit, implying investment losses elsewhere in the group. The company described its cash reserve (cash, cash equivalents, short-term investments and other cash positions) as ample. The Waterdrop charity platform's social commitments continued alongside the commercial business.